An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia

Investigators
Kraus, Carl
Institutions
Arrevus, Inc.
Start date
2019
End date
2020
Objective
Project Summary Infectious disease is the third-leading cause of death in the United States, and hospital-acquired infections(HAIs) in particular affect 1.7 million patients annually. The most common type of HAI is pneumonia, often causedby multi-drug resistant (MDR) pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiellapneumoniae, Escherichia coli, and Acinetobacter baumannii. Rates of antibiotic resistance for these bacteria inhospital- and ventilator-acquired pneumonia (HAP and VAP, respectively) have escalated significantly, in somecases exceeding 45%. There is a clear and urgent unmet medical need for new therapeutic strategies totreat HAP and VAP that can improve patient outcomes and combat the rising rates of antibiotic resistanceassociated with HAIs. As a novel approach to address this expanding medical need, Arrevus is pioneering the development ofDesigner Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs). The lead compound, ARV-1501, imparts its antimicrobial activity in two distinct ways; i) disrupting the bacterial lipid membrane and ii)specifically inhibiting the bacterial chaperone protein DnaK, a highly conserved prokaryotic heat-shock proteincritical for bacterial survival in stress conditions. In preliminary studies, ARV-1502 has demonstrated broad-spectrum antimicrobial activity against a range ofGram-negative and Gram-positive bacterial pathogens. ARV-1502 has also demonstrated the ability to reversebacterial resistance to legacy antibiotics. In the proposed Phase I program, Arrevus will conduct a series ofstudies to characterize the antibiotic activities of ARV-1502 both in vitro and in vivo in order to assess thepotential of ARV-1502, alone and in combination with an antibiotic, to treat HAP and VAP. In Aim 1, we will use in vitro studies to define the spectrum of activity of ARV-1502 alone (Aim 1A) and incombination with clinically-utilized antibiotics (Aim 1B) against antibiotic-sensitive and antibiotic-resistant strainsof P. aeruginosa. In Aim 2, we will assess ARV-1502 alone and as an adjuvant therapy with the meropenem ina mouse model of pneumonia. In Aim 2A, ARV-1502 will be administered as a monotherapy to characterizeefficacy and dosing for co-treatment in Aim 2B. The collective data from this Phase I effort will define ARV-1502?s ability, alone or with an antibiotic, to treatpneumonia that is typically resistant to legacy antibiotics. These proof-of-concept data are critical to supportfurther development of ARV-1502 in a Phase II program that would be geared toward performing extensive invivo efficacy and safety studies to assess ARV-1502 as a therapeutic option for treating MDR-associated HAPand VAP.
Funding Source
Nat'l. Inst. of Allergy and Infectious Diseases
Project source
View this project
Project number
1R41AI142726-01A1
Accession number
142726
Categories
Sanitation and Quality Standards